arrow
A

Annarita Miccio

inserm umr1163
H指数:34
被引数:3,872

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Case Report: Recurrence of recipient-derived erythropoiesis in hematopoietic stem cell transplant for sickle-cell anemia: multi-lineage chimerism analysis as a tool to distinguish atypical pure red cell aplasia from poor erythroid engraftment

病例报告:镰状细胞贫血造血干细胞移植中受者来源的红细胞生成复发:多系嵌合体分析作为区分非典型纯红细胞再生障碍与红系植入不良的工具

2026-09-260
OA
Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the HBG1/2 promoters

通过HBG1/2启动子中的抑制因子-激活因子基序转换增强γ-球蛋白再激活和镰状细胞纠正

2026-06-060
OAAI
Clinical application of base editing for treating β-thalassaemia

碱基编辑在β-地中海贫血治疗中的临床应用

Nature
IF48.5
2026-04-080
PRE
Base editing of β0-thalassemia mutations as a therapeutic strategy for severe β-hemoglobinopathies

β0-地中海贫血突变的碱基编辑作为一种治疗严重β-血红蛋白病的策略

2025-11-260
PRE
VEXAS syndrome anemia is a mosaic erythroblastopenia

VEXAS综合征贫血是一种镶嵌性红系祖细胞减少症。

Blood
IF23.1
2025-09-220
PRE
A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease

一种用于重写γ-球蛋白启动子并重新激活胎儿血红蛋白以治疗镰状细胞病的碱基编辑策略

Blood
IF23.1
2025-08-280
OAAI
Advancing the Integration of ‘Basic/Fundamental’ and Translational Cellular and Gene Therapy Science within the EBMT: Accelerating the Pathway to Progress

推进EBMT内“基础/根本”与转化细胞及基因治疗科学的整合:加速通往进步的路径

2025-08-070
PRE
Severe inflammation and lineage skewing are associated with poor engraftment of engineered hematopoietic stem cells in patients with sickle cell disease

严重炎症和谱系偏移与 sickle cell disease 患者中工程化造血干细胞的植入不良相关。

2025-04-010
OA
Advanced delivery systems for gene editing: A comprehensive review from the GenE-HumDi COST Action Working Group

基因编辑的先进递送系统: 基因-HumDi成本行动工作组的全面审查

2025-03-010
OAAI
Non-viral DNA delivery and TALEN editing correct the sickle cell mutation in hematopoietic stem cells
2024-06-113
OAAI
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
2023-12-013
OAAI